Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Metrics to compare | JANX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJANXPeersSector | |
---|---|---|---|---|
P/E Ratio | −14.6x | −4.3x | −0.7x | |
PEG Ratio | 0.15 | 0.12 | 0.00 | |
Price/Book | 1.6x | 2.4x | 2.6x | |
Price / LTM Sales | 3,523.5x | 41.8x | 3.4x | |
Upside (Analyst Target) | 173.9% | 121.4% | 37.8% | |
Fair Value Upside | Unlock | 1.7% | 5.5% | Unlock |